The foundation of Dr. Kilian Pohl's laboratory is computational science aimed at identifying biomedical phenotypes improving the mechanistic understanding, diagnosis, and treatment of neuropsychiatric disorders. The biomedical phenotypes are discovered by unbiased, machine learning-based searches across biological, neuroimaging, and neuropsychological data.

Dr. Robbie Majzner's laboratory focuses on engineering CAR T cells and other immunotherapeutics for children with cancer. Dr. Majzner has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2, B7-H3, and ALK. Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting.

Dr. Gheorghe Chistol's lab studies how eukaryotic cells replicate their DNA, and how the replication machinery copes with various challenges during this process. They use single-molecule approaches to understand the mechanisms that safeguard the integrity of our genomes, and what happens when these mechanisms fail.

The Good lab uses tools from statistical physics, population genetics, and computational biology to understand how microscopic growth processes and genome dynamics at the single cell level give rise to the collective behaviors that can be observed at the population level.

Dr. Molly Schumer's lab studies the evolution of natural populations, focusing on the how the process of hybridization impacts the evolution of genomes and species.

Dr. Tamar Green's lab focuses on pediatric clinical neuroscience, with an emphasis on neurogenetic and neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders. The principal aim of their research program is to uncover the effects of genetic variation and associated downstream pathways on human brain development.

Dr. Lawrence Fung is a child and adolescent psychiatrist with specialized clinical training in autism spectrum disorder (ASD) and advanced research training in chemical engineering, neuropsychopharmacology, and neuroimaging. He has extensive work experience in pharmaceutical research and development, including the discovery and development of a GABA(A) receptor agonist for the treatment of insomnia and anxiety.

Dr. Monther Abu-Remaileh's lab is interested in identifying novel pathways that enable cellular and organismal adaptation to metabolic stress and changes in environmental conditions. The lab also studies how these pathways go awry in human diseases such as cancer, neurodegeneration and metabolic syndrome, in order to engineer new therapeutic modalities.

Dr. Inma Cobos is a neuropathologist and neuroscientist with expertise in neurodegeneration. Her research program combines her background in diagnostic neuropathology, knowledge of developmental neuroscience, and state-of-the-art cellular and molecular technologies to advance the understanding of Alzheimer’s disease and related dementias. She is currently applying single-cell methods to human brain to dissect the contributions of distinct cell types to Alzheimer’s disease pathogenesis and investigate the mechanisms of tau-mediated neurodegeneration in human brain.

Dr. Ansuman Satpathy's research focuses on developing new genome sequencing technologies to study immune system function and dysfunction directly in cancer patients. His work employs both single-cell and three-dimensional genome sequencing tools to study the epigenetic regulation of tumor-specific T cells.